Yahoo Finance

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual ...

WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...
Yahoo Finance

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

WATERTOWN, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...
Mena FN

Werewolf Therapeutics To Present Updated Data From Phase 1/1B Clinical Trial Of WTX-124 As Monotherapy And In Combination With Pembrolizumab In Solid Tumors At 2024 ASCO Annual ...

(MENAFN- GlobeNewsWire - Nasdaq) - Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy ...
Mena FN

Werewolf Therapeutics To Present Data From Ongoing Phase 1/1B Clinical Trial Of WTX-124 As Monotherapy And In Combination With Pembrolizumab In Solid Tumors

(MENAFN- EIN Presswire) - WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single ...